You just read:

Wellspring Biosciences Announces Clearance of IND Application to Initiate Phase 1 Trial of KRAS G12C Mutant Inhibitor ARS-3248

News provided by

Wellspring Biosciences, Inc.

May 16, 2019, 08:00 ET